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PURPOSE: Hemodialysis in patients with chron- 
ic liver disease and ascites may be complicated 
by intradialytic hypotension, limiting the 
amount of ultrafiltration and resulting in mas- 
sive ascites. Successful maintenance peritoneal 
dialysis (PD) has not been previously reported 
as an alternative to hemodialysis in this 
population. 
PATIENTS AND METHODS: Nine patients with 
chronic renal failure, chronic liver disease, and 
tense ascites prior to begking PD are de- 
scribed. All chronic PD catheters were placed 
percutaneously by the nephrology staff. Seven 
patients were maintained primarily on continu- 
ous ambulatory peritoneal dialysis, whereas two 
were on intermittent peritoneal dialysis. 
RESULTS: PD catheters were placed without se- 
rious hemorrhage or bowel injury. PD provided 
adequate clearance and volume maintenance for 
each patient. Fifteen episodes of peritonitis oc- 
curred in 18 patient-years of PD. All episodes of 
peritonitis were successfully treated with intra- 
peritoneal antibiotics without catheter removal. 
Only one patient had a decline in the serum al- 
bumin level of 0.5 g/dL or more during the 
course of chronic PD. Three of the nine patients 
are still alive and on PD for durations of 18 to 24 
months. One patient insidiously developed scle- 
rosing peritonitis after 8 years on PD and is now 
on hemodhdysk, and another patient switched to 
hemodialysis because she was no longer able to 
care for herself or to manage her PD. Four pa- 
tients died while maintained on PQ three deaths 
were due to complications of liver failure within 
the first 4 months of PD and the fourth was due 
to empyema after 4 years of PD. 
CONCLUSION: PD can be used successfully to 
treat chronic renal failure in patients with 
chronic liver disease and ascites when the liver 
From the Department of Internal Medicine, Division of Nephrology. 
University of Michigan, Ann Arbor, Michigan. 
Requests for reprints should be addressed to Roy G. Marcus, M.D., 
Division of Nephrology, MSRB 2, Room 1560, 1150 West Medical Center 
Drive, Ann Arbor, Michigan 48109. 
Manuscript submitted October 23, 1991, and accepted in revised form 
February 18.1992. 
disease itself is not rapidly fataL PD may be bet- 
ter tolerated than hemodialysis and perhaps 
should be the renal replacement treatment of 
choice in these patients. 
P atients with chronic liver disease and ascites who require dialysis for acute or chronic renal 
failure pose difficult management problems. Hemo- 
dialysis in these patients may be complicated by 
intradialytic hypotension, limiting the amount of 
ultrafiltration and resulting in massive ascites 
[l-3]. These patients are also at high risk for gastro- 
intestinal bleeding, which can be exacerbated by 
anticoagulation. 
Peritoneal dialysis (PD) may have several dis- 
tinct advantages in treating patients with chronic 
liver disease and ascites, including slow and contin- 
uous ultrafiltration using equilibration PD tech- 
niques, direct removal of ascitic fluid, and avoid- 
ance of anticoagulation. Despite these theoretic 
considerations, there are few reports of mainte- 
nance PD in such patients. Potential disadvantages 
that may have limited the use of PD in these pa- 
tients include the fear of excessive bleeding follow- 
ing catheter placement, inefficient ultrafiltration 
and solute removal in the presence of massive asci- 
tes, and protein loss through the peritoneal mem- 
brane [4]. 
Nine patients with chronic liver disease and asci- 
tes have been treated successfully with mainte- 
nance PD at our institution, and this report serves 
to describe these cases and review the pertinent 
literature. 
PATIENTS AND METHODS 
The records of the PD unit of the University of 
Michigan were reviewed, and all patients with both 
chronic renal failure and liver disease were identi- 
fied. All patients who had evidence of chronic liver 
disease and ascites at the time of initiation of PD 
were included in this retrospective review. Ascites 
was defined by the presence of a fluid wave or shift- 
ing dullness on physical examination, or by evi- 
dence of ascites on abdominal computed tomo- 
graphic (CT) scan or ultrasound. 
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TABLE I 




H/O Pugh y;;.ig Albumin 
(g/dL) Ascites Enceph (5-15) %Z’ 
1 ETOH, biopsy-proven cirrhosis Small kidneys at presentation 3 3.0 Tense No 9 Yes/No 
2 Biopsy-proven cirrhosis Polycystic kidney disease <2 >3.5 Tense No 7 Yes/No 
3 Biopsy-proven cirrhosis Polycystic kidney disease t2 3.3 Tense No 8 No 
4 ETOH, small liver FSGS <2 >3.5 Tense No 7 No 
5 ETOH ? Hepatorenal syndrome 2 1.8 Tense Yes 12 Yes/Yes 
6 Chronic hepatitis B Small kidnevs at oresentation <2 3.5 Tense No 8 Yes/Yes 
7 ETOH, small liver, history of SBP Insulin-dependent diabetes mellitus t2 2.2 Tense No 9 No 
8 Primarv amvloidosis, hepatomeRalv Primarv amvloidosis <2 2.0 Tense No 9 No 
9 ETOH, biopsy-proven cirrhosis ? Hepatorenal syndrome 8 2.9 Tense Yes 14 Yes/Yes 
0 Enceph = history of hepatic encephalopathy; Pugh = Pugh modification swre of the Child-Turcotte classification system f51; Variceslbleecl = presence of esophageal varices/history of vancei 
ading; ETOH = alcohol-related liver disease; FSGS = focal and segmental glomerular sclerosis; SBP = spontaneous bacterial peritonitis. 
Nine patients were identified who met these cri- 
teria among the 465 patients treated in our chronic 
PD program between 1980 and 1990. Table I shows 
the etiology of liver disease and renal disease in our 
patients. Table II shows the clinical characteristics 
of liver disease in our patients including the Pugh 
modification score of the Child-Turcotte classifica- 
tion system, which describes the severity of cirrho- 
sis [5]. All nine patients had a history of tense asci- 
tes prior to initiating PD. Seven patients were 
maintained primarily on continuous ambulatory 
peritoneal dialysis, whereas two were on intermit- 
tent peritoneal dialysis. 
RESULTS 
Insertion of PD Catheter 
All chronic PD catheters were placed percutane- 
ously in a paramedian location by the nephrology 
staff using a stainless steel trochar technique before 
1985, and using a guide wire and peel-away sheath 
technique after 1985 [6]. There were no serious 
hemorrhagic complications or bowel injuries. Five 
TABLE II 
Adequacy and Duration of Dialysis 
KT/V* f$u$rati~; Tey Duration of 
Patient Modality (per wk1 . U~U Urea Peritoneal Dialysis Outcome 
1 CAPD 0.9 - 4Y Died-empyema 
2 CAPD 1.3 91% 8~ Sclerosing peritonitis, changed to HD 
3 CAPD 1.6 78% 18mo Still on CAPD 
4 CAPD 1.3 - 2Y Still on CAPD 
5 CAPD 2.7 80% 2Y Still on CAPD 
6 CAPD 1.2 - 2 mo Died-liver failure 
7 CAPD 1.5-1.7 82% 9mo Inability to care for herself, changed to HD 
8 IPD - - 4 mo Died-cardiac arrest 
9 IPD - - 3 mo Died-hepatic encephalopathy 
rea/Purea = dialysate urea/plasma urea; CAPD = continuous ambulatory peritoneal dialysis; IPD = intermrttent parituneal dialysis; HD = hemodialysis. 
T/V = 709 x DDDV t 1.44 x C,)/total body water [71. The dally dialysate drain volume (DDDV) was estimated as the prescribed exchange volume plus 500 ml for each exchange as an &mate of 
rafiltration. This volume was multiplied by 0.9 to estimate the equrllbration of urea at 4 to 5 hours average exchange time. Residual renal function (Cr) is known for Patient 5 only. 
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patients had elevated prothrombin times (14.1, 
14.6,15.1,16.3, and 26 seconds), and bleeding times 
were not checked routinely prior to catheter inser- 
tion. Eight catheters were curled, double-cuff de- 
vices, and one was a double-cuff straight catheter. 
Due to immediate dialytic needs, six catheters were 
used for low volume, short intraperitoneal dwell 
time dialysis on the day of insertion. One of these 
six patients (Patient 7) developed a small leak at 
the insertion site that resolved after 2 days without 
PD. There were no leaks in the three patients whose 
catheter use began after a 7- to lo-day break-in 
period. Patient 7 had unsuspected spontaneous 
bacterial peritonitis with Klebsiella pneumonia at 
the time of catheter insertion. The catheter was left 
in place, and the infection was successfully treated 
with intraperitoneal antibiotics. 
Duration of PD 
Table II shows the duration of PD and the reason 
for termination for each patient. Three of the nine 
patients are still alive and on PD with durations of 
18 to 24 months Two patients switched to hemodi- 
alysis. One of these patients insidiously developed 
sclerosing peritonitis after 8 years on PD. The other 
patient switched to hemodialysis because she was 
no longer able to care for herself or to manage her 
PD, even though her PD course had been medically 
uncomplicated. Incidentally, while on hemodialy- 
sis, she continued to use her chronic PD catheter for 
intermittent drainage of symptomatic ascites. Four 
patients died while maintained on PD; three of 
these deaths were due to complications of liver fail- 
ure within the first 4 months of treatment and the 
fourth was associated with empyema and possibly 
related to chronic PD after 4 years of treatment. 
Adequacy of Dialysis 
All patients were maintained without uremic 
symptoms while on PD except Patient 2 when she 
developed sclerosing peritonitis. Blood urea nitro- 
gen (BUN) ranged from 40 to 70 mg/dL in seven 
patients. BUN was 80 to 95 mg/dL in Patient 5 and 
was less than 70 mg/dL in Patient 2 until she devel- 
oped sclerosing peritonitis when her BUN in- 
creased to 125 mg/dL and necessitated switching to 
hemodialysis. Table II lists the weekly urea index 
shown as KT/V (K = clearance of urea; T = time of 
dialysis; V = volume of distribution of urea) for 
each patient [7]. Several patients had residual urine 
output; however, only Patient 5 had a 24-hour urine 
collection to quantify the residual renal function 
(C,), and thus the KT/V calculations in the other 
patients may underestimate the total clearance. 
Four patients had 3-hour peritoneal equilibration 
tests to assess their peritoneal transport kinetics. 
The ratio of dialysate urea to plasma urea (D,,,J 
P,& ranged from 78% to 91% except in Patient 2 
after the onset of sclerosing peritonitis, when her 
D&P,,,, decreased from 91% to lo%, with the av- 
erage 3-hour D,,,JP urea in our program averaging 
0.81 f 0.08 (unpublished data). We have not been 
able to obtain a peritoneal equilibration test on Pa- 
tient 4 since he is a prison inmate, and the other 
four patients either died too early in the course to 
assess KTIV adequately or died during the period 
prior to regular KT/V and peritoneal equilibration 
test evaluations. 
Hematocrit, another marker of dialysis adequa- 
cy, was less than 30% in five patients at the time of 
PD initiation. One of these patients had a increase 
from 26% to 33% after starting PD, and the others 
had stable hematocrits without the need for trans- 
fusions. Hematocrits were also stable in those pa- 
tients who began with a hematocrit greater than 
30%. 
Pleural Effusion 
Two patients developed large chronic right pleu- 
ral effusions. A radiolabeled peritoneogram in Pa- 
tient 9 showed that peritoneal fluid flowed into his 
right pleural space. A similar study was not done in 
Patient 1. Patient 1 died secondary to a right empy- 
ema. Patient 9’s death was unrelated to his pleural 
effusion. 
Hernia 
Patient 5 had an umbilical hernia at the time of 
catheter insertion, which was repaired 3 month8 
later. Three patients developed hernias after begin- 
ning PD. Patient 2 developed an incisional hernia, 
which was repaired. Patient 4 developed an umbili- 
cal hernia, which improved with a decrease in ex- 
change volume. Patient 9 developed a large umbili- 
cal hernia, which could not be repaired secondary to 
hi8 poor general condition. All hernia repairs were 
successful, no hernias recurred, and patients con- 
tinued with chronic PD therapy. 
Peritonitis 
There were 15 episode8 of peritonitis in a total of 
18 patient-years of PD. Seven infections were due 
to coagulase-negative staphylococci, one was due to 
a coagulase-positive staphylococci, four were due to 
Esherichia coli, and one due to a nonspecified 
gram-negative rod. Two infections were treated 
without obtaining a culture prior to initiation of 
antibiotic therapy. Seven infections required inpa- 
tient hospitalizations because the patients were be- 
lieved to be too ill for outpatient management; how- 
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1 2 4 8 
YEARS OF CAPD 
ever, no patient needed care in the intensive care 
unit. All episodes were successfully treated with in- 
traperitoneal antibiotics without catheter removal. 
There were no episodes of hepatic encephalopathy 
associated with peritonitis episodes. 
Hypoalbuminemia 
Figure 1 shows the course of serum albumin in 
eight of nine patients, excluding Patient 6 who sur- 
vived only 2 months. Only one patient had a de- 
crease in the serum albumin level of 0.5 g/dL or 
more during the course of chronic PD. In all other 
cases, the serum albumin level remained stable 
through courses ranging from 4 months to 8 years. 
Dry weight, another indicator of nutritional ade- 
quacy, was stable or increased in all patients while 
maintained on PD, except for Patient 1 who lost 40 
pounds in the 6 months prior to his death after 
having a stable weight for 3.5 years. 
COMMENTS 
Acute and chronic renal failure frequently com- 
plicate chronic liver disease. Although hypotension 
is frequent during hemodialysis in these patients 
[l-3], it is surprising that successful maintenance 
PD has not been reported as an alternative to hemo- 
dialysis in this population. The successful use of 
acute PD has been described in case reports of pa- 
tients with chronic liver disease and in patients with 
fulminate acute liver disease &lo]. However, the 
largest series of acute PD in patients with liver dis- 
ease had discouraging results. All of the 20 cirrhotic 
Figure 1. End point status: *Alive; 
Vhanged to hemodialysis; §Died. 
patients died prior to hospital discharge, and only 
six of the 50 patients with fulminate acute liver 
disease survived [l]. This study also described five 
cirrhotic patients with acute renal failure treated 
with hemodialysis, all of whom died. PD has been 
used to treat noncirrhotic end-stage renal disease 
patients with hemodialysis-related ascites. These 
patients also have frequent hypotension during he- 
modialysis; however, they do not have liver disease 
or portal hypertension [ll-141. 
We have successfully utilized maintenance PD in 
nine patients with chronic renal failure and chronic 
liver disease complicated by ascites. All of our pa- 
tients had their peritoneal catheters placed percu- 
taneously at the bedside. Although cirrhotic pa- 
tients are potentially at greater risk of hemorrhagic 
complications secondary to the combination of ab- 
dominal wall varices, uremic platelet dysfunction, 
and clotting factor deficiency, we encountered no 
serious hemorrhagic complications. We also had 
minimal problems with leakage of dialysate despite 
early utilization of the catheters. Similar results 
have been reported for placement of stiff acute PD 
catheters in cirrhotics, although most of these pre- 
vious reports have described catheters placed for 
short-term ultrafiltration and peritoneal reinfusion 
of ascitic fluid in patients with massive ascites with 
or without uremia [1,9,10,X-18]. 
In our series, five of nine patients survived on PD 
for at least 18 months with good control of uremic 
symptoms and volume status. Three of these pa- 
tients are currently doing well on PD. These good 
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results occurred despite low weekly clearances of 
urea, as measured by the KT/V calculations [19,20]. 
These patients were treated before we used kinetic 
analysis to help determine our PD prescriptions. 
Since the patients appeared to be clinically well 
dialyzed on their PD regimens using primarily 1.5-L 
exchanges, we did not increase their exchanges to 2 
L. Furthermore, the calculated KT/V may have 
substantially underestimated the amount of total 
clearance for these patients since residual renal 
function was not measured [19]. 
The survival of our patients compares favorably 
with the expected survival of cirrhotic patients in 
general. The Pugh modification score of the Child- 
Turcotte classification for our patients’ liver dis- 
ease is shown in Table II. Patients with a score 
between 7 to 9 have been reported to have an 80% l- 
year survival rate, and patients with a score greater 
than nine have a 45% l-year survival rate [5]. How- 
ever, these survival rates are in patients without 
chronic renal failure, and renal failure likely im- 
poses a substantial disadvantage to survival overall. 
In addition, three of our patients had a history of 
hemorrhage from esophageal varices, a strong risk 
factor for early mortality in chronic liver disease 
[21-231. Two of these patients survived for only 2 to 
3 months after beginning PD. 
The rate of peritonitis in our patients, one epi- 
sode every 1.2 patient-years, is similar to that of 
previous reports for PD patients in general [24]. 
Although spontaneous bacterial peritonitis is a 
well-known precipitator of hepatic encephalopa- 
thy, our patients did not develop hepatic encepha- 
lopathy during 15 episodes of PD-associated perito- 
nitis. This difference may have been due to early 
diagnosis of peritonitis in PD patients, to the inter- 
mittent peritoneal lavage with each dialysis fluid 
exchange, or to inherent pathogenic differences be- 
tween PD peritonitis, a common skin organism in- 
fection from an external source, and spontaneous 
bacterial peritonitis, a serious enteric infection 
from internal sources. In addition, it is possible that 
PD removes some of the toxin that causes hepatic 
encephalopathy, akin to reports of temporary im- 
provement in some patients with hepatic encepha- 
lopathy following high-permeability hemodialysis 
[25,26]. Also, the patient who had spontaneous bac- 
terial peritonitis found unexpectedly at the time of 
catheter placement did well with intraperitoneal 
antibiotics and ongoing PD without catheter 
removal. 
Only two of our patients had complications of PD 
that contributed to the death of one patient and led 
to discontinuation of chronic PD in the other. One 
patient had a chronic pleural effusion that became 
infected, leading to his death after 4 years of PD. 
Pleural effusions are reported to occur in 1.6% of 
PD patients without pre-existing liver disease [27] 
and are common in cirrhotic patients not on dialysis 
[28]. Although a large abdominal volume secondary 
to ascites accumulation and PD fluid could lead to 
high intra-abdominal pressure and hence an in- 
creased tendency for translocation of fluid through 
small holes in the diaphragm, this patient did not 
have tense ascites while on PD. The other patient 
developed sclerosing, calcifying peritonitis. She had 
only one episode of peritonitis during her 8 years of 
PD. Whether portal hypertension in addition to 
chronic peritoneal exposure to hypertonic solutions 
played a pathogenic role in the development of scle- 
rosing peritonitis is unknown. 
In summary, this report demonstrates that PD 
can be successfully used to treat end-stage renal 
disease in patients with chronic liver disease and 
ascites. PD may be better tolerated than hemodial- 
ysis, and perhaps should be the renal replacement 
treatment of choice in these patients since it elimi- 
nates the need for anticoagulation, controls ascites 
accumulation, may prevent serious complications 
from spontaneous bacterial peritonitis, and can of- 
ten be associated with excellent long-term survival 
and sustained nutrition in patients whose liver dis- 
ease itself is not rapidly fatal. 
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